

ASX ANNOUNCEMENT  
ASX:VHL OTCQB:VHLUF

16 May 2025

## Section 708A Cleansing Notice

Vitasora Health Limited (ASX:VHL; OTCQB:VHLUF) ("Vitasora Health" or the "Company"), advises that it has issued 1,750,000 fully paid ordinary shares ("Shares").

### Section 708A Cleansing Notice

In accordance with section 708A(5)(e) of the Act, the Company gives notice that:

1. the Shares were issued without disclosure to investors under Part 6D.2 of the Act;
2. as at the date of this notice, the Company has complied with the provisions of Chapter 2M of the Act, as they apply to the Company and sections 674 and 674A of the Corporations Act 2001 (Cth); and
3. as at the date of this notice there is no information that is 'excluded' information within the meanings of section 708A(7) and 708A(8) of the Act, being information:
  - a) that has been excluded from a continuous disclosure notice in accordance with the ASX Listing Rules;
  - b) that investors and their professional advisers would reasonably require for the purposes of making and informed assessment of:
    - i. the assets and liabilities, financial position and performance, profits and losses and prospects of the Company; or
    - ii. the rights and liabilities attaching to the Securities.

-ENDS-

For further information, investors and media please contact:

**Mr Marjan Mikel**  
CEO & Managing Director  
Vitasora Health Limited  
P: +61 408 462 873  
E: [marjan@vitasorahealth.com](mailto:marjan@vitasorahealth.com)

**Mr Nicholas Smedley**  
Chairman  
Vitasora Health Limited  
P: +61 447 074 160  
E: [nicholas@vitasorahealth.com](mailto:nicholas@vitasorahealth.com)

*This ASX announcement has been authorised for release by the Board of Directors of Vitasora Health Limited.*

---

#### About Vitasora Health Limited – A Revolutionary Remote Healthcare Solutions Provider

Vitasora Health Limited (ASX:VHL, OTCQB:VHLUF) is redefining digital Connected Care in the U.S. healthcare market. We combine cutting-edge technologies and expert clinical teams to deliver a turnkey solution for providers. Our remote patient monitoring (RPM) and chronic care management (CCM) services improve outcomes, reduce costs, and help healthcare clients thrive in a value-based world. Partnering with healthcare providers and organisations we empower our clients to extend exceptional care into the community, making a real difference to patients' lives.

We are revolutionising healthcare one patient at a time with our disruptive business model, which provides personalised and responsive care. Our cutting-edge R&D sets us apart, offering comprehensive Connected Care Management programs for all major chronic conditions, including our exclusive remote wheeze detection for respiratory disorders.

Through strategic partnerships, we seamlessly integrate our advanced solutions into existing systems and workflows, boosting efficiency and significantly reducing overall healthcare costs. Our data-driven programs and superior clinical expertise position us at the forefront of chronic disease management, ensuring patients' healthcare needs are met consistently and effectively across the continuum of care.

## ASX ANNOUNCEMENT

ASX:VHL OTCQB:VHLUF

Learn more at [www.vitasorahealth.com.au](http://www.vitasorahealth.com.au)

### About the wheezo® Medical Device

wheezo®, a world-first FDA-approved Class II medical device, is the sole WheezeRate detector capable of integrating into RPM programs. Developed by Vitasora, wheezo® utilises innovative technology to analyse breath sounds for wheeze. The device works with the user-friendly respi™ app, enabling users to log symptoms and triggers. The wheezo® system creates a comprehensive and individualised patient profile, fostering informed dialogues between patients and physicians. For details on our US offering, visit <https://respiri.co/us/> or for [wheezo®](#)

Vitasora Health Limited is headquartered in Melbourne with offices in Los Angeles.

wheezo® is a registered trademark of Vitasora Health Limited

### Forward Looking Statements

Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on Vitasora current expectations, estimates and projections about the industry in which Vitasora operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the control of Vitasora, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. Vitasora cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Vitasora only as of the date of this release. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. Vitasora will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.